Compagnie Lombard Odier S Cm A Neu Base Therapeutics, Inc. Transaction History

Compagnie Lombard Odier S Cm A

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$7.25 - $9.71 $2,066 - $2,767	-285 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$4.77 - $8.23 $405 - $699	85 Added 42.5%	285 $2,000
Q3 2019 Nov 12, 2019	BUY	$3.15 - $6.59 $630 - $1,318	200 New	200 $1,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Compagnie Lombard Odier S Cm A, based on Form 13F filings with the SEC.

Stay updated on Compagnie Lombard Odier S Cm A with notifications on news.